Gastroenterology
Volume 129, Issue 2 , Pages 745-748 , August 2005

Colon Cancer Screening Guidelines 2005: The Fecal Occult Blood Test Option Has Become a Better FIT

  • James E. Allison

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to: James E. Allison, MD, Clinical Professor of Medicine UCSF, Division of Gastroenterology, San Francisco General Hospital, 1001 Potrero Avenue, NH-3D, Oakland, California 94110. fax: (415) 641-0745.

References 

  1. Morikawa T , Kato J , Yamaji Y , Wada R , Mitsushima T , Shiratori Y . Comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population . Gastroenterology . 2005;125:422–428
  2. Imperiale TF , Ransohoff DF , Itzkowitz SH , Turnbull BA , Ross ME . Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population . N Engl J Med . 2004;351:2704–2714
  3. Ahlquist DA, Sargent DJ, Levin TR, Rex DK, Ahnen D, Knigge KL, et al. Stool DNA screening for colorectal cancer (prospective multicenter comparison with hemoccult) . Gastroenterology . 2005;128(Suppl 2):A63
  4. Allison JE , Tekawa IS , Ransom LJ , Adrain AL . A comparison of fecal occult blood tests for colorectal cancer screening . N Engl J Med . 1996;334:155–159
  5. Allison JE, Levin TR, Sakoda L, Tucker J, Pauly MP, Shlager L, et al. The new fecal occult blood tests have poor application sensitivity for significant polyps in average risk subjects . Gastroenterology . 2002;122(Suppl 1):A592
  6. Fleisher M , Winawer SJ , Zauber AG , Smith C , Schwartz MK  National Polyp Study Work Group . Accuracy of fecal occult blood test interpretation . Ann Intern Med . 1991;114:875–876
  7. Niv Y . Fecal Occult blood test (the importance of proper evaluation) . J Clin Gastroenterol . 1990;12:393–395
  8. Selinger RRE , Norman S , Dominitz JA . Failure of health care professionals to interpret fecal occult blood tests accurately . Am J Med . 2003;114:64–67
  9. Jaffe RM , Kasten B , Young DS , MacLowry JD . False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C) . Ann Intern Med . 1975;83:824–826
  10. Cole SR , Young GP . Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer . Med J Aust . 2001;175:195–198
  11. Pignone M , Saha S , Hoerger T , Mandelblatt J . Cost-effectiveness analyses of colorectal cancer screening (a systematic review for the U.S. Preventive Services Task Force) . Ann Intern Med . 2002;137:96–104
  12. Ransohoff DF . ColonCancer Screening in 2005 (status and challenges) . Gastroenterology . 2005;128:1685–1695
  13. Fletcher RH . Commentary . ACP Journal Club . 1996;124:74
  14. Cole SR , Young GP , Esterman A , Cadd B , Morcom J . A randomized trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer . J Med Screen . 2003;10:117–122
  15. Smith A , Young G , Cole S , Morcom J , Chandler H , La Pointe L . A quantifiable fecal immunochemical test (FIT) for hemoglobin facilitates balancing sensitivity with specificity when screening for colorectal cancer . Gastroenterology . 2004;126(Suppl 2):S1346
  16. Smith RA , von Eschenbach A , Wender R , et al.   American Cancer Society guidelines for the early detection of cancer . CA Cancer J Clin . 2001;51:38–75
  17. Screening for Colorectal Cancer (recommendation and rationale US preventive services task force) . Ann Intern Med . 2002;137:129–131
  18. Winawer SJ , Fletcher RH , Rex D , Bond J , Burt R , et al.   Colorectal cancer screening and surveillance (clinical guidelines and rationale U. S multisociety task force on colorectal cancer) . Gastroenterology . 2003;124:544–560
  19. National research council on the economic models of colorectal cancer screening in average-risk adults. (http://www.nap.edu/catalog/11228.html).
  20. Lieberman DA . Colonoscopy (as good as gold?) . Editorial Ann Intern Med . 2004;141:401–403
  21. Ransohoff DF . Lessons from the UK sigmoidoscopy screening trial . Editorial Lancet . 2002;359:1266–1267
  22. Stryker S , Wolff B , Culp C , et al.   Natural history of untreated colonic polyps . Gastroenterology . 1987;93:1009–1013
  23. Eide T . Risk of colorectal cancer in adenoma bearing individuals within a defined population . Int J Cancer . 1986;38:173–176
  24. Rex DK , Rahmani EY , Haseman JH , Lemmel GT , Kaster S , Buckley JS . Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice . Gastroenterology . 1997;112:17–23
  25. Bressler B , Paszat LE , VindenC  , Li C , He J , Rababeck L . Colonoscopic miss rates for right-sided colon cancer (a population-based analysis) . Gastroenterology . 2004;127:452–456
  26. Pickhardt PJ , Nugent PA , Mysliwiec PA , Choi JR , Schindler WR . Location of adenomas missed by optical colonoscopy . Ann Intern Med . 2004;141:352–359
  27. Robertson DJ . Colorectal cancer in patients under close colonoscopic surveillance . Gastroenterology . 2005;129:34–41
  28. Bampton PA, Sandford JJ, Cole SR, Smith A, Morcom J, Cadd B, et al. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology . Gut . 2005;54:803–806
  29. Atkin WS , Saunders BP . Surveillance guidelines after removal of colorectal adenomatous polyps . Gut . 2002;51:6–9
  30. Seef LC, Manninen DL, Dong FB, Chattopadhyay SK, Nadel MR, Tangka FKL, et al. Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population of the United States? . Gastroenterology . 2004;127:1661–1669
  31. Levin TR . Colonoscopy capacity: Can we build it? Will they come? . (Editorial) Gastroenterology . 2004;127:1841–1849
  32. Woolf SH . The best screening test for colorectal cancer-a personal choice . Editorial N Engl J Med . 2000;343:1641–1643
  33. Allison JE . Screening for colorectal cancer 2003 (is there still a role for the FOBT?) . Tech Gastrointest Endosc . 2003;5:127–133
  34. Lieberman DA , Weiss DG , Bond JH , Ahnen DJ , et al.   Use of colonoscopy to screen asymptomatic adults for colorectal cancer . N Engl J Med . 2000;343:162–168
  35. Macafee DAL , Scholefield JH . Population based endoscopic screening for colorectal cancer . Gut . 2003;52:323–326
  36. Lewis JD , Asch DA . Barriers to office-based screening sigmoidoscopy; does reimurbursement cover costs? . Ann Intern Med . 1999;130:525–530
  37. Shaheen NJ , Ransohoff DF . Sigmoidoscopy costs and the limits of altruism . Am J Med . 1999;107:286–287
  38. Ahlquist DA , Skoletsky JE , Boynton KA , Harrington JJ , Mahoney DW , Pierceall WE , et al.   Colorectal cancer screening by detection of altered human DNA in stool (feasibility of a multitarget assay panel) . Gastroenterology . 2000;119:1219–1227
  39. Woolf SH . A smarter strategy? Reflections on fecal DNA screening for colorectal cancer . (Editorial) N Engl J Med . 2004;351:2755–2758
  40. Fletcher RH . Screening sigmoidoscopy-How often and how good? . Editorial JAMA . 2003;290:106–108
  41. http://www.preventcancer.org/colorectal/aboutcolorectal/healthcare_providers.cfm
  42. Young GP , St. John JB , Winawer SJ , Rozen P . Choice of fecal occult blood tests for colorectal cancer screening (recommendations based on performance characteristics in population studies) . Am J Gastroenterol . 2002;97:2499–2507

 Dr. Allison is on the Scientific Advisory Board of Enterix Corportation.

PII: S0016-5085(05)01196-0

doi: 10.1053/j.gastro.2005.06.034

Gastroenterology
Volume 129, Issue 2 , Pages 745-748 , August 2005

Article Tools